GSK Argues Its Strategy Is Delivering As Still More Cuts Are Made, Including in R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Witty suggests group has emerged from worst of patent storm with an upbeat forecast for 2010 and promises of further cost-cutting.